Kalia Kumud, Chief Information Officer of Guardant Health (GH), has filed 49 Form 4 transactions in the company’s stock, revealing a pronounced sell-side bias. Across all filings, Kumud has sold approximately $5.4 million worth of GH shares while making just one open-market purchase of $78,456. The bulk of the selling activity is clustered in recent months, with notable open-market sales on June 10, 2026 ($652,030 and $78,516), June 11, 2026 ($445,155.53), and June 15, 2026 ($78,648). The largest single sale occurred on March 4, 2026, when two transactions totaled $3.81 million, accompanied by option exercises valued at $448,000.
The transaction pattern is dominated by non-discretionary and mechanical events rather than conviction trades. Of the 49 filings, the majority are coded as "M" (option exercises, valued at $0 in most cases), "F" (shares withheld for tax, totaling over $1.6 million), and "A" (compensation grants). These codes indicate routine equity compensation management rather than active positioning. The only true open-market purchase—$78,456 on June 15, 2026—was immediately followed by a sale of nearly the same amount ($78,648) on the same day, suggesting a wash or offsetting transaction rather than a bullish signal.
Recent activity reinforces the sell-heavy trend. In the last two months, Kumud has executed six open-market sales against a single purchase, with the most recent transactions on June 15, 2026, including a tax-withholding event of $40,763.48 and four option exercises. The absence of any open-market buys since June 15, combined with the steady stream of sales and tax-related disposals, points to a consistent reduction of GH exposure. While the data does not indicate any irregular or suspicious timing, the overwhelming ratio of sales to purchases—$5.4 million sold versus $78,456 bought—highlights a clear net divestment pattern by the company’s CIO over the filing period.
AI-assisted summary